B cell receptor inhibitor causes chronic lymphocytic leukemia remission

A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

Read the whole article on Physorg

More from Physorg